CPRX Form 144 Notice: 26,000 Common Shares Planned Sale on NASDAQ

Rhea-AI Filing Summary

Catalyst Pharmaceuticals filed a Form 144 notice indicating a proposed sale of 26,000 common shares through Fidelity Brokerage Services LLC with an aggregate market value of $525,087.81. The filing lists the approximate date of sale as 08/27/2025 and names NASDAQ as the securities exchange. It records the number of shares outstanding as 122,391,010. The securities are reported as acquired by an option granted 12/19/2018 with an acquisition date shown as 08/27/2025, and the consideration on sale noted as cash. Several issuer and filer identification fields in the provided content are blank or not shown in the excerpt.

Positive

• Disclosure provided for a proposed sale of 26,000 common shares including broker, aggregate value, and sale date
• Acquisition details are reported (option grant dated 12/19/2018) which aids traceability of the shares' origin

Negative

• None.

Insights

Securities Compliance Analyst

TL;DR: Routine Rule 144 notice disclosing a proposed sale of 26,000 common shares via a broker on NASDAQ.

The Form 144 provides the minimum information required for a Rule 144 notice: class of security, broker name and address, number of shares to be sold, aggregate market value, shares outstanding, intended sale date, and acquisition details citing an option grant. Several identifying fields for filer and issuer are absent from the excerpt, which limits verification. From a compliance perspective, the filing appears to follow the standard structure but recipients should confirm the filer identity and ensure the filing is properly submitted and signed in the full record.

Equity Markets Analyst

TL;DR: Small, disclosed insider/affiliate sale notice; informational but not clearly material on its face.

The notice documents a proposed transaction valued at $525,087.81 for 26,000 shares, which the filing explicitly reports. The document does not include recent sales in the prior three months and identifies the securities as acquired by an option granted in 2018. No earnings, operational, or market-impacting details are present. This is a routine disclosure that provides transparency about potential share supply but contains no information that, by itself, indicates a material change to the company’s fundamentals.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	26000	525087.81	122391010	08/27/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/27/2025	Option Granted - 12/19/2018	Issuer			26000	08/27/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Catalyst Pharmaceuticals (CPRX) report in this Form 144?

The filing reports a proposed sale of 26,000 common shares through Fidelity Brokerage Services LLC with an aggregate market value of $525,087.81 and an approximate sale date of 08/27/2025.

Which exchange is the proposed sale listed for in the Form 144?

The Form 144 lists NASDAQ as the securities exchange for the proposed sale.

How were the shares being sold acquired according to the filing?

The securities are reported as acquired via an option granted on 12/19/2018 with an acquisition date shown as 08/27/2025 and the nature of payment for sale listed as cash.

Does the filing show other sales by the same person in the past three months?

The filing states "Nothing to Report" for securities sold during the past three months by the person for whose account the securities are to be sold.

What identifying information about the filer or issuer is included?

The broker name and address, number of shares outstanding, and some transaction details are included; however, several filer and issuer identification fields in the excerpt are blank or not provided.